D Peer, JM Karp, S Hong, OC Farokhzad, R … - Nature nanotechnology, 2007 - health.toodoc.com 1Immune Disease Institute and Department of Anesthesia, Harvard Medical School,
Boston, Massachusetts 02115, USA; 2HST Center for Biomedical Engineering,
Department of Medicine, Brigham and Women's Hospital, Harvard Medical ... Cited by 106 - Related articles - View as HTML - BL Direct - All 9 versions
- ►hematologylibrary.org R Stasi, G Del Poeta, E Stipa, ML … - Blood, 2007 - bloodjournal.hematologylibrary.org Rituximab, an anti-CD20 monoclonal antibody, has been used to treat autoimmune
disorders such as idiopathic thrombocytopenic purpura (ITP). However, its
mechanisms of action as well as the effects on cellular immunity remain ... Cited by 65 - Related articles - BL Direct - All 2 versions
B Garvey - British Journal of Haematology, 2008 - interscience.wiley.com Current treatment regimens for haematological autoimmune diseases are relatively
non-selective and are often associated with considerable toxicity. Recently, it
has become clear that B cells play a key role in both the development and ... Cited by 45 - Related articles - BL Direct - All 5 versions
- ►hematologylibrary.org JB Bussel, DJ Kuter, V Pullarkat, RM Lyons, M … - Blood, 2009 - bloodjournal.hematologylibrary.org Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet
counts and mucocutaneous bleeding. In previous studies romiplostim (AMG531), a
thrombopoiesis-stimulating protein, increased platelet counts in most ... Cited by 36 - Related articles - All 6 versions
MC Levesque, EW St. Clair - The Journal of Allergy and Clinical Immunology, 2008 - Elsevier Recent advances have led to the development of mAbs that effectively deplete B
cells in human beings and target pathways essential for B-cell development. B
cell–directed therapies represent promising treatments for autoimmune ... Cited by 31 - Related articles - All 23 versions
- ►hematologylibrary.org [PDF] G Emilia, M Luppi, P Zucchini, M Morselli, L … - Blood, 2007 - bloodjournal.hematologylibrary.org . Hematology; all rights reserved Copyright 2007 by The American Society of 200,
Washington DC 20036. semimonthly by the American Society of Hematology, 1900 M
St, NW, Suite Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published Cited by 30 - Related articles - BL Direct - All 4 versions
- ►hematologylibrary.org F Rodeghiero, R Stasi, T Gernsheimer, M … - Blood, 2009 - bloodjournal.hematologylibrary.org Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely
dependent on clinical expertise and observations more than on evidence derived
from clinical trials of high scientific quality. One major obstacle to the ... Cited by 33 - Related articles - All 3 versions
- ►hematologylibrary.org B Godeau, R Porcher, O Fain, F Lefrere, P … - Blood, 2008 - bloodjournal.hematologylibrary.org Whether rituximab could effectively and safely avoid splenectomy for adults with
chronic immune thrombocytopenic purpura (ITP) remains unresolved. A multicenter,
prospective, open-label, single-arm, phase 2 trial was conducted to assess ... Cited by 28 - Related articles - All 4 versions
- ►haematologica.com D Provan, T Butler, ML Evangelista, S … - Haematologica, 2007 - haematologica.com We conducted a retrospective analysis of 11 consecutive patients with various
autoimmune cytopenias who failed to respond to conventional treatments and
received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive ... Cited by 28 - Related articles - BL Direct - All 9 versions
B Godeau, D Provan, J Bussel - Current opinion in hematology, 2007 - journals.lww.com Recent findings: Recent studies suggest that most patients with immune
thrombocytopenic purpura have a disease that is generally well tolerated, with
little morbidity. Splenectomy remains the best 'curative' treatment for ... Cited by 26 - Related articles - BL Direct - All 3 versions
